Omidenepag isopropyl

(Omlonti®)

Omidenepag isopropyl

Drug updated on 11/15/2023

Dosage FormSolution (topical ophthalmic; 0.02 mg/mL (0.002%))
Drug ClassRelatively selective prostaglandin E2 receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Product Monograph / Prescribing Information

Document TitleYearSource
Omlonti (omidenepag isopropyl ophthalmic solution) Prescribing Information.2022Santen Incorporated, Emeryville, CA

Systematic Reviews / Meta-Analyses